In summary, since DNA methylation regulation is reversible, DNA demethylating agents may be an effective means of treating cancer in future and modulation of RGS2, RGS10 and RGS17 expression could be a promising approach to enhance the chemotherapeutic drug activity against drug-resistant cancer cells. Here, RGS17 is linked to cancer.